NATIONAL CENTER FOR HIV/AIDS, DERMATOLOGY AND STD (NCHADS) has floated a tender for Provision Technical Assistance for NCHADS-SI HIV Program. The project location is Cambodia and the tender is closing on 21 May 2024. The tender notice number is 29580, while the TOT Ref Number is 100467993. Bidders can have further information about the Tender and can request the complete Tender document by Registering on the site.

Expired Tender

Procurement Summary

Country : Cambodia

Summary : Provision Technical Assistance for NCHADS-SI HIV Program

Deadline : 21 May 2024

Other Information

Notice Type : Tender

TOT Ref.No.: 100467993

Document Ref. No. : 29580

Competition : ICB

Financier : Global Fund to Fight AIDS, Tuberculosis and Malaria (GFFATM)

Purchaser Ownership : Public

Tender Value : Refer Document

Purchaser's Detail

Name :Login to see tender_details

Address : Login to see tender_details

Email : Login to see tender_details

Login to see details

Tender Details

Expression of Interest are invited for Provision Technical Assistance For NCHADS-SI HIV Program

The National Centre for HIV/AIDS, Dermatology and STD (NCHADS) is the legally accountable Sub-Implementer of the Global Fund Program to implement the "Rapidly march toward and ending AIDS as a public Health threat by 2025, Increase Access to and improve Quality of TB Diagnosis and treatment and OD and community levels with Linkages to TB-HIV in Cambodia. NCHADS is looking for quality Technical Assistance (TA) from either a national/international service provider or firm in provision of technical assistance for HIV program. .

Background

Cambodia has made significant progress in its HIV response and, in 2017, achieved the 2020 Fast-Track treatment targets of 90-90-90, with 82% of people living with HIV (PLHIV) knowing their status, 89% of those who know their status being on treatment, and 79% of those on treatment being virally suppressed. In the area of mother to child transmission (MTCT), HIV testing coverage among antenatal (ANC) attendees in 2018 was 88.4% and 85% of pregnant women (PW) living with HIV on antiretroviral therapy (ART).

Documents

 Tender Notice